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Abstract Uncoupling protein 3 (UCP3) is a member of the
mitochondrial carrier superfamily, preferentially expressed in
skeletal muscle. Its function is not fully understood and it is
debated whether it uncouples oxidative phosphorylation as
does UCP1 in brown adipose tissue. Recent evidences suggest
a role for UCP3 in the £ux of fatty acids in and out mitochon-
dria and their utilization in concert with mitochondrial thioes-
terase-1 (MTE-1). In fact, mice overexpressing muscle UCP3
also show high levels of MTE-1. Feno¢brate is a hypolipidemic
drug that prevents body weight gain in diet-induced obese rats
and enhances lipid metabolism by activating peroxisome prolif-
erator-activated receptors (PPARs). Because fatty acids and
feno¢brate stimulate PPARs and in turn UCP3, we investigated
whether UCP3 expression might be induced ‘de novo’ in situa-
tions of increased hepatic mitochondrial fatty acid utilization
caused by a combined e¡ect of a high-fat diet and feno¢brate
treatment. We also investigated whether Mte-1 expression and
L-oxidation were a¡ected. We show here that Ucp3 is induced in
liver of feno¢brate-treated rats at the mRNA and protein level.
Expression was restricted to hepatocytes and was unevenly dis-
tributed in the liver. No increase in cell proliferation, in£amma-
tory or ¢brotic responses was found. Mte-1 expression and mi-
tochondrial L-oxidation were upregulated. Thus, Ucp3 can be
transactivated in tissues where it is normally silent and feno¢-
brate can attain this e¡ect in liver. The data demonstrate that
UCP3 is involved in fatty acid utilization and support the notion
that UCP3 and MTE-1 are linked within the same metabolic
pathway. 2 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Maintenance of a stable body weight depends on the bal-
ance between energy intake and expenditure and is governed
by genetic, physiological and behavioral factors [1]. The dis-
covery of uncoupling proteins (UCPs), and their isoforms
(UCP1^5) in animal and human tissues prompted studies of
the mechanisms that regulate energy expenditure [2^4].
UCP1 was the ¢rst member of these mitochondrial carriers
to be identi¢ed and its function in thermogenesis is well es-
tablished. In brown adipose tissue it dissipates the proton
gradient across the inner mitochondrial membrane [2].
UCP2 is widely distributed in a number of tissues and cell
types. Albeit its high homology with UCP1 and overexpres-
sion experiments in yeast demonstrating uncoupling activity,
the biological role of UCP2 is still debated [5]. UCP3 is pre-
dominantly expressed in skeletal muscle and may be impor-
tant in energy balance. Mice overexpressing UCP3 are hyper-
phagic and lean with increased mitochondrial proton
conductance [6]. In contrast, body weight was una¡ected in
mice in which the UCP3 gene was ablated, despite increased
mitochondrial respiration coupling in skeletal muscle [7].
UCP3 function appears then not completely elucidated.
Based on its hypothesized uncoupling function, several studies
have investigated this activity in situations where UCP3 ex-
pression was physiologically altered but contrasting results
have been obtained [8^11]. Recent evidences indicate that
UCP3 may play functional roles unrelated to the basal un-
coupling [12]. In conditions of elevated lipid metabolism,
UCP3 might export fatty acid anions, released from an excess
of acyl-coenzyme A (CoA) by mitochondrial thioesterase-1
(MTE-1), from the mitochondrial matrix to the cytosol [13].
Thus, UCP3 gene may be important in situations where
L-oxidation becomes the main metabolic pathway.
Feno¢brate, a hypolipidemic drug that activates peroxisome
proliferator-activated receptors (PPARs), in particular the
K-isoform, prevents and reduces body weight gain in diet-in-
duced obese rats [14,15]. This e¡ect is due to enhanced lipid
catabolism in the liver mainly through PPARs transcriptional
induction of the genes for mitochondrial and peroxisomal oxi-
dative enzymes [16]. UCP genes contain functional PPAR-
responsive elements [17,18] and may be targets of feno¢brate.
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Because fatty acids and feno¢brate stimulate PPARK and in
turn UCPs, we investigated whether UCP3 expression was
induced in rat liver when hepatic lipid metabolism is strongly
enhanced by the combined e¡ect of the high-fat diet and fe-
no¢brate. Such a condition, that is metabolically and not
genetically determined, would contribute to identify a role
for UCP3.
2. Materials and methods
2.1. Animal treatment and tissue sampling
Eight-week-old male Wistar rats (Charles River, Lecco, Italy),
weighing about 200 g, were used in this study. The animals, housed
in a conventional temperature-controlled animal room (28‡C), one per
cage, on a 12 h light^darkness cycle, were treated according to the
national guidelines regarding animal experiments and underwent
1 week of adaptation. They were divided into four groups of seven
rats each and monitored for 2 months. During this time, group C was
kept on the standard diet (15.9 kJ gross energy/g), and group D, DF1,
and DF2 were fed a palatable high-fat diet (19.8 kJ gross energy/g)
[19]. Groups DF1 and DF2 were also fed feno¢brate (kindly provided
by Fournier Pharma, SpA., Segrate, Italy) at a dose of 320 mg/kg
body weight daily suspended in 0.1% carboxymethylcellulose. DF1
rats received the drug only during the second month of dietary treat-
ment, while DF2 rats received feno¢brate for 2 months. C and D rats
were fed the suspension vehicle once a day. Body weight and food
intake were monitored daily. Animals were weighed and decapitated.
Excised liver and gastrocnemius muscles were weighed, snap-frozen in
liquid nitrogen and stored at 380‡C.
2.2. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
Total RNA was extracted from frozen tissues [15]. Superscript1 II
(Life Technologies Italia, San Giuliano Milanese, Italy) was used to
reverse transcribe 2 Wg of RNA and was omitted in the negative
controls. cDNAs were ampli¢ed by standard PCR, using primers
selective for UCP3 and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), used for normalization as previously reported [15]. Spe-
ci¢c primers for rat MTE-1 were as follows: CCTCGTCTTTC-
GCTGTCCTG (sense), GTGTCCGTCCAGCACCTCCA (antisense).
The Mte-1 DNA fragment was ampli¢ed by running 35 cycles of 40 s
at 95‡C, 50 s at 61‡C, and 50 s at 72‡C using 1.5 mM MgCl2, and 5%
DMSO. PCR products were 662, 452, and 876 bp long DNA frag-
ments for UCP3, MTE-1, and GAPDH genes, respectively.
2.3. Mitochondrial protein extracts and Western blotting
About 500 mg of frozen tissue were homogenized and processed for
mitochondrial protein extraction as previously described [10]. Western
blot analysis was carried out on 30 Wg of protein for each sample
incubated with a rabbit anti-human UCP3 polyclonal antibody
(1:500 dilution; Research Diagnostic, Inc., Flanders, NJ, USA). De-
tection was obtained by chemiluminescence (Amersham Pharmacia
Biotech Italia, Cologno Monzese, Italy).
2.4. Histochemistry and immunohistochemistry
4-Wm-thick sections from formalin-¢xed, para⁄n-embedded liver
specimens were used for histochemical analysis using the hematoxy-
lin^eosin staining. Immunohistochemistry was performed after heat-
induced antigen retrieval for all antibodies. The antibodies used were:
anti-UCP3 (the same antibody used for Western blotting, 1:200 dilu-
tion), proliferating cell nuclear antigen (mouse anti-human PCNA
monoclonal antibody, PC10; 1:200 dilution; Dako, Carpinteria,
CA, USA), PPARK (rabbit anti-human PPARK polyclonal antibody;
dilution 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA). Immunodetection was performed with a biotinylated secondary
antibody, followed by peroxidase-labelled streptavidin (LSAB-
DAKO, Carpinteria, CA, USA) with diaminobenzidine chromogen
as substrate. Steatosis was evaluated by hematoxylin^eosin staining
which resulted in visualization of vacuoles in hepatocytes and was
expressed as percentage of vacuolized hepatocytes (for each high
power ¢eld (HPF), considering at least 10 HPF). In£ammation was
evaluated by the number of Kup¡er cells per HPF (at least 10 HPF
were evaluated) in portal, periportal and intra-acinar regions. Fibrosis
was evaluated as presence/absence of signi¢cant amounts of collagen
¢bers stained with Red Sirius in the portal and periportal regions as
described [20]. The proliferation index was the mean percentage of
PCNA-positive cells in 10 HPF (40U). The distribution of UCP3 and
PPARK was measured in the portal space area (zone 1), central vein
area (zone 3) and in the intermediate area (zone 2).
2.5. Mitochondrial preparation, measurement of fatty acid-dependent
respiration and determination of the kinetic response of the proton
leak to changes in membrane potential
Liver specimens were homogenized; after di¡erential centrifuga-
tions, mitochondria were isolated at 3000Ug. The isolated organelles
were used for fatty acid-dependent respiration (L-oxidation) and res-
piratory control ratio (RCR) measurements, as previously reported
[9]. Membrane potential (v8) was determined from the distribution
of the lipophilic cation triphenylmethylphosphonium (TPMPþ), which
was measured using a TPMPþ-sensitive electrode [21]. To measure the
basal proton leak the incubation medium was supplemented with 1%
w/v fatty acid-free bovine serum albumin (BSA). To evaluate the
kinetic response of the mitochondrial proton leak to a change in
v8, we supplemented the incubation medium with oligomycin and
the respiration rate was inhibited by sequential addition of malonate
up to 2.5 mM.
2.6. Statistics
Results are expressed as meansPS.E.M. The statistical signi¢cance
of di¡erences between groups was determined by ANOVA followed
by a Student^Neuman^Keuls test. The level of signi¢cance was set at
P6 0.05.
3. Results
3.1. Feno¢brate regulates UCP3 mRNA and protein levels
To determine whether feno¢brate modulates UCP3 gene
expression, we analyzed by RT-PCR total RNA extracted
from the gastrocnemius muscle and liver of rats kept as de-
scribed. Ucp2 mRNA levels in liver and Ucp3 mRNA levels in
skeletal muscle did not di¡er in feno¢brate-treated and con-
trol animals (data not shown) as previously shown [15]. Un-
expectedly, Ucp3 transcription was induced in the livers of
rats treated with feno¢brate, for 1 or 2 months (Fig. 1A, lanes
DF1 and DF2). Interestingly, Ucp3 induction was detected
also in rats treated with feno¢brate and fed a standard control
chow diet (data not shown). Ucp3 mRNA was instead absent
from livers of animals fed a standard diet (C) or a high-fat
diet (D). The same result was obtained when the PCR was
carried out in saturating conditions, i.e. for 45^50 cycles.
To verify that the Ucp3 mRNA induction was paralleled by
an increase in the corresponding protein, we analyzed mito-
chondria-enriched liver extracts from rats of the four groups
by Western blotting. A band of the apparent molecular weight
of 33 kDa was detected only in extracts from the livers of
feno¢brate-treated rats fed a high-fat diet (Fig. 1B, lanes
DF1 and DF2) and a standard chow diet (data not shown).
No Ucp3 signal was detected in rats not treated with feno¢-
brate, whereas a band of the same molecular weight was
found in the mitochondria-enriched extracts prepared from
the gastrocnemius muscle, which served as positive control.
The intensity of this signal remained unchanged in mitochon-
dria-enriched extracts from muscle of treated and control rats
(data not shown) and in general was similar in extracts from
rats of the same group, indicating a low variability among
individuals.
3.2. Feno¢brate upregulates Mte-1 in liver
The same liver cDNAs obtained as described were used to
amplify a speci¢c Mte-1 fragment. The high-fat diet was as-
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Fig. 1. UCP3 mRNA and protein expression in rat liver. A: RT-PCR analysis of UCP3 gene expression in liver from rats on a standard diet
(C), high-fat diet (D), high-fat diet plus feno¢brate administered for 1 (DF1) or 2 months (DF2). GAPDH ampli¢ed in parallel served as inter-
nal control. The negative control was loaded in lane B. The size marker (M) is shown on the left. B: Western blotting analysis of UCP3 in liv-
er mitochondrial protein extracts from C, D, DF1, and DF2 rats. Mitochondrial protein extracts from skeletal muscle of a rat on a standard
diet were used as a positive control. The molecular weight marker is shown on the right. C: RT-PCR analysis of MTE-1 gene expression in
rat liver. M, C, D, DF1, DF2, and B are as in panel A.
Fig. 2. Immunohistochemistry detection of UCP3 in liver. 4-Wm-thick liver sections of rats fed a high-fat diet (D), and high-fat diet plus feno¢-
brate administered for 2 months (DF2) were treated with hematoxylin^eosin, immunostained with an antibody against UCP3 and visualized
with the chromogen diaminobenzidine. The three panels reported for each group represent the portal space area (zone 1), the central vein area
(zone 3) and the intermediate area between zones 1 and 3 (zone 2). Only sections from feno¢brate-treated rats (DF2) stained positive; the sig-
nal was particularly intense and widespread in the cytoplasm of the cells around the vessels.
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sociated to a small, not signi¢cant, increase of Mte-1 mRNA
levels. However, the addition of feno¢brate to the dietary
regimen increased the Mte-1 mRNA by 3.9- and 3.6-fold after
1 and 2 months of treatment, respectively.
3.3. Histochemistry and immunohistochemistry
Liver sections from treated and control animals were ana-
lyzed to con¢rm Ucp3 expression and to identify the cells
where induction occurred (Fig. 2). UCP3 was detected only
in the hepatocytes from groups DF1 and DF2 (only sections
of DF2 rats are shown). Interestingly, zone 1 and zone 3 (the
portal and center-lobular region, respectively) were intensely
stained, whereas the interconnecting zone 2 showed only a
slight staining. There was no staining in liver of rats fed a
standard or a fat-enriched diet (groups C and D).
Hepatic steatosis was signi¢cantly higher in groups D and
DF1 than group C (Table 1). Di¡erently, the amount of fat in
hepatocytes of DF2 animals was clearly reduced, even though
each individual cell remained enlarged. The proliferating in-
dex, as measured by PCNA-positive cells, was similar in all
groups, indicating no increase in cell proliferation. Likewise,
there were no di¡erences among the groups in the number
neither of Kup¡er cells (an index of the in£ammatory re-
sponse) nor in the size and amount of collagen ¢bers (a ¢-
brotic index), ruling out chronic hepatitis or incipient cirrho-
sis.
3.4. Mitochondrial L-oxidation rate and proton leak kinetics
Feno¢brate treatment induced a signi¢cant increase in liver
mitochondrial L-oxidation rate as compared to animals on the
high-fat or the standard diet. The values of State 4 were
20.7P 0.9, 12.4 P 0.9 and 13.0 P 1.5 (natoms oxygen/min/mg
protein) in groups DF2, D and C, respectively. These values
correspond to an increase of 68% in DF2 as compared to D
rats (P6 0.05). The RCR values were 5.4 P 0.4, 4.3 P 0.4 and
5.1P 0.1 for DF2, D, and C rats, respectively (P=not signi¢-
cant). There were no di¡erences in the kinetic responses of the
proton leak to changes in v8 in liver mitochondria from D
and DF2 rats in the presence of fatty acid-free BSA (Fig. 3).
4. Discussion
The UCP3 gene, predominantly expressed in muscle, is in-
volved in energy homeostasis [2]. It could be a molecular
determinant of the T3-regulated resting metabolic rate [10]
and mice overexpressing UCP3 in muscle are lean and hyper-
phagic [6]. In this latter model, the white adipose tissue mass
was reduced, as in our system based on the e¡ects of feno¢-
brate on diet-induced obese rats [15]. However, under no cir-
cumstances UCP3 was detected in liver. Here we present the
¢rst experimental evidence that UCP3 protein expression can
be induced in a cell where it is normally silenced. The e¡ect is
mediated by feno¢brate at mRNA and protein levels. Immu-
Table 1
Histochemical and immunohistochemical analysis of livers from C, D, DF1, and DF2 rats
Group PCNAa Steatosisa Collagen ¢bers Kup¡er cellsb UCP3
zone 1 zone 2 zone 3 zone 1 zone 2 zone 3
C 5% 6 5% N N 3 1 3 3 3
C 8% 10% N N 3 1 3 3 3
C 10% 7% N N 3 2 3 3 3
C 15% 6 5% N N 3 1 3 3 3
D 15% 25% N N 3 1 3 3 3
D 25% 30% N N 3 3 3 3 3
D 5% 40% N N 3 1 3 3 3
D 5% 30% N N 3 1 3 3 3
DF1 20% 30% N N 3 1 3 3 +
DF1 5% 20% N N 3 1 + 3 +
DF1 15% 35% N N 3 1 + 3 +
DF1 10% 40% N N ^ 2 3 3 ++
DF2 10% 20% N N 3 2 ++ ++ +++
DF2 15% 10% N N 3 1 ++ + +++
DF2 15% 15% N N 3 1 ++ + +++
DF2 10% 15% N N 3 1 ++ + +++
4-Wm-thick formalin-¢xed, para⁄n-embedded liver sections were evaluated for steatosis, in£ammation (Kup¡er cells) and ¢brosis. UCP3 and
PCNA were detected by immunohistochemistry. PCNA was used as a proliferation index. += 6 10% of immunopositive hepatocytes (250U).
++= s 10%, 6 20% of immunopositive hepatocytes (250U). +++= s 20% of immunopositive hepatocytes (250U). N=normal.
a% of hepatocytes (450U).
bEvaluated for 10 hepatocytes.
Fig. 3. Kinetic response of the proton leak to changes in membrane
potentials (v8). The analysis was carried out in liver mitochondria
incubated with 1% BSA: comparison between D and DF2 rats is
shown. Each point represents the meanPS.E.M. of duplicate deter-
minations in four di¡erent mitochondrial preparations.
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nohistochemical analysis con¢rmed that the gene is induced in
hepatocytes. Interestingly, UCP3-positive staining was more
abundant in liver zones 1 and 3 than in zone 2. Similar results
were obtained with PPARK (data not shown), thereby linking
UCP3 and PPARK expression. This pattern might re£ect the
accumulation of the ligand deriving from the intestine in zone
1 and after di¡usion through the hepatic lobular system in
zone 3. Additional histochemical and immunohistochemical
data ruled out that cell proliferation, in£ammation and ¢bro-
sis occurred in liver.
The mechanisms regulating Ucp3 expression in di¡erent tis-
sues and its silencing in liver are unknown. In liver of feno¢-
brate-treated animals, de novo gene induction has been re-
ported only for the lipoprotein lipase gene [22]. Tissue-
speci¢c factors may be responsible for this expression pattern.
Because PPARs regulate UCP gene expression [17,18], it is
possible that the PPREs in UCP genes have a low binding
a⁄nity for the liganded PPAR. Consequently, inordinately
high concentrations of the correct ligand can transactivate
target genes. Feno¢brate may ful¢ll this function. Alterna-
tively, at the dose used, feno¢brate may promiscuously acti-
vate PPARQ present at low levels in hepatocytes that in turn
may activate the UCP3 gene. Finally, pathways distinct from
PPAR activation might regulate feno¢brate-mediated UCP3
gene expression.
Whatever the mechanism underlying UCP3 gene activation,
it remains to be established whether ‘basal uncoupling’ is the
primary function of the protein [9,23^25]. In our feno¢brate-
treated animals, the mitochondrial proton leak kinetics, mea-
sured in the presence of albumin, did not show marked di¡er-
ences between the D and DF1 or DF2 groups. This ¢nding
indicates a lack of basal uncoupling activity due to UCP3, in
agreement with previous data [9,26]. However, the extreme
points of the curves, corresponding to the minimum and max-
imum State 4 oxygen consumption, showed a lower mitochon-
drial membrane potential in feno¢brate-treated animals
(p6 0.05). This result, coupled with the RCR decrease (even
if not signi¢cant) in mitochondria from the same rats, would
suggest a possible increase in the basal proton leak due to
feno¢brate and UCP3. Nevertheless, we do not support this
possibility because a signi¢cant di¡erence should be found for
all oxygen consumption states. The lack of a basal uncoupling
activity in vitro, on the other hand, does not exclude that
UCP3 might catalyze an inducible proton conductance when
activated by some cofactors such as coenzyme Q, free fatty
acids (FFA) and reactive oxygen species in vivo [27,28]).
Alternatively, UCP3 may play functional roles not strictly
related to the uncoupling. UCP3 can act as a FFA transloca-
tor and a role as a regulator of lipids as fuel substrate has
been hypothesized in situations where lipid metabolism pre-
dominates [12]. In concert with MTE-1 that would produce
FFA3 and CoASH from acyl-CoA molecules, UCP3 would
export the FFA3 molecule from the mitochondrial matrix to
the cytosol. Therefore, su⁄cient levels of CoASH molecules
will become available for L-oxidation and tricarboxylic acid
cycle, especially when high rates of fatty acid oxidation occur
in the cell. The three-fold increase in MTE-1 mRNA in mice
overexpressing UCP3 further supported this hypothesis. In
our experimental conditions, feno¢brate induces de novo ex-
pression of UCP3, no variations in UCP2 mRNA, more than
a three-fold increase in MTE-1 expression and a signi¢cant
elevation (68%) in mitochondrial L-oxidation in liver. These
results provide strong evidence that UCP3 and MTE-1 are
linked within the same metabolic pathway as regulators of
fatty acid metabolism.
These data further explain why feno¢brate causes reduction
of body weight in our experimental setting [15]. The exported
FFA3 anions can be activated to acyl-CoA and either trans-
ported back into the mitochondria or metabolized by peroxi-
somes whose number and activity are strongly induced by
feno¢brate [15,29]. The cytoplasmic fatty acid activation
would require ATP hydrolysis and a concomitant entry of
Hþ, generating a futile ATP hydrolysis and a Hþ re-entry,
if any, with the net result of a reduced ATP production and
additional energy wasting.
In conclusion, we demonstrate a de novo expression of
UCP3 in liver, provide evidence that UCP3 and MTE-1
may concur in regulating fatty acid metabolism and enhanc-
ing energy dissipation in liver mitochondria and describe a
suitable animal model to deepen comprehension of the phys-
iological role of UCP3. The ¢ndings reported might prompt
studies aimed at verifying whether feno¢brate or other com-
pounds interfere with energy metabolism in man.
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